Man Group
STLN

Man Group’s Starling Oncology STLN Stock Holding History

Man Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-378,963
Closed -$3.76M – 2109
2021
Q3 		$3.76M Hold
378,963
– – 0.01% 960
2021
Q2 		$3.77M Hold
378,963
– – 0.01% 1006
2021
Q1 		$3.77M Hold
378,963
– – 0.02% 831
2020
Q4 		$4.09M Hold
378,963
– – 0.02% 916
2020
Q3 		$3.93M Buy
+378,963
New +$3.94M 0.02% 931

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Man Group's STLN Position: Q4 2021 in Review

Man Group sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 378,963 shares — an estimated $3.76M sold.

Man Group first reported a position in STLN in Q3 2020 and held it in 5 quarters. The position peaked at $4.09M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Man Group reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • Man Group sold 378,963 Starling Oncology shares in Q4 2021, an estimated $3.76M.
  • Man Group first reported a position in Starling Oncology in Q3 2020 and held it in 5 quarters.
  • Man Group's Starling Oncology position peaked at $4.09M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Man Group's 13F filing for Q4 2021, filed 14 Feb 2022.